Trevi Therapeutics

Forecast & Rating11 analysts currently cover Trevi Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $28.18, about 54.1% upside from the current price of $18.29. Price targets range from $23.00 to $40.00 — a wide spread, showing clear disagreement over just how much Trevi Therapeutics can rise. Historically, about 24.8% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Trevi Therapeutics closely still see room for the stock to rise. Data as of Aug 14, 2026; for reference only and not investment advice.